^
    Back
    Association details:
    Biomarker:XRCC2 mutation
    Cancer:Colorectal Cancer
    Drug:oxaliplatin (DNA synthesis inhibitor, DNA cross linking agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Dig Med Res
    Title:

    Combined olaparib and oxaliplatin inhibits tumor proliferation by cell cycle arrest and cell apoptosis in XRCC2-defecient colorectal cancer

    Published date:
    12/31/2019
    Excerpt:
    Cell proliferation of XRCC2-defecient CRC cell lines was restrained by combination treatment rather than olaparib or oxaliplatin alone.
    DOI:
    10.21037/dmr.2019.12.02